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Status epilepticus secondary to glioma
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1. Introduction
Brain tumor related epilepsy is an important aspect of the
burden of disease for patients with glioma and often pose a
therapeutic challenge. The risk of epileptic seizures is 70–90% for
patients with low grade glioma (LGG) and 30–60% for patients with
high grade glioma (HGG) [1–5]. In this study, we explored status
epilepticus (SE) in a prospective patient database with glioma and
epilepsy. SE is a life-threatening medical emergency in which
seizure activity continues for a prolonged period of time, or where
seizures recur before full clinical recovery from the preceding
seizure [6,7]. The Commission on Classification and Terminology
and the Commission on Epidemiology of the International League
Against Epilepsy (ILAE) have proposed a new definition of SE:
Status epilepticus is a condition resulting either from the failure of
the mechanisms responsible for seizure termination or from the
initiation of mechanisms, which lead to abnormally, prolonged
seizures. It is a condition which can have long-term consequences,
including neuronal death, neuronal injury, and alteration of
neuronal networks, depending on the type and duration of
seizures [8]. SE is often operationally defined as 5 min of
continuous seizure or two or more discrete seizures between
which there is incomplete recovery of consciousness [9]. If
inadequately treated and lasting beyond 30 min, which is the
older definition of SE, this condition can result in permanent
pathophysiological changes [6,10]. Thus, SE requires immediate
treatment, often in an intensive care unit (ICU). Brain tumor is the
cause of SE in 3–12% of adult cases [11–14]. Previous studies on SE
in glioma patients [15–18] have been retrospective, of small
sample size and including tumors of various histologies.
The aim of our study was to investigate SE in a prospective
material of adult patients with verified glioma. We investigated the
relationship of SE to tumor grading, seizure semiology, trigger
factors and treatment response, in addition to recurrence and
outcome. Our research is important to gain a better understanding
of this challenging epileptic condition in a patient group with
complicating underlying tumor.
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A B S T R A C T
Purpose: Epilepsy is common in glioma patients, but clinical data on the course of status epilepticus (SE)
in this group are sparse. The aim of this study was to investigate the relationship of SE to tumor grading,
seizure semiology, trigger factors, treatment response, recurrence and outcome of SE in patients with
glioma.
Methods: Adult patients with SE and glioma WHO grade II–IV were identified from a prospective clinical
study at two neurological departments. We identified 31 SE in 20 patients during a period of 7 years.
Results: SE was more frequent in patients with high-grade glioma. Half of the seizures were secondary
generalized. Patients with a clinical and radiological stable glioma had SE as often as patients with
untreated tumor or tumor in progression. The majority of patients had a well-controlled epilepsy prior to
SE. SE responded well to first and second line treatment. Patients with SE and tumor progression were
not more refractory to treatment than patients without progression.
Conclusion: SE secondary to glioma responded well to treatment and should be treated aggressively
regardless of the oncological prognosis. Seizures during tumor progression were not more treatment
refractory than SE in patients with stable glioma disease.
 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Abbreviations: AEDs, antiepileptic drugs; GBM, glioblastoma; HGG, high grade
glioma; LGG, low grade glioma; RSE, refractory status epilepticus; SE, status
epilepticus.
* Corresponding author at: Department of Neurology, Haukeland University
Hospital, 5021 Bergen, Norway. Tel.: +47 97564429; fax: +47 55975164.
E-mail address: kristinmkb@hotmail.com (K.M. Knudsen-Baas).
Contents lists available at ScienceDirect
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1059-1311/ 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
2. Material and methods
Patients with SE and glioma were identified from a prospective
clinical study of adult patients with verified glioma WHO grade II–
IV and one or more epileptic seizures during the course of disease.
The study has been ongoing since 2008 with inclusion of all eligible
patients at the only two neurological departments in two counties
of western Norway (Haukeland University Hospital in Bergen,
Hordaland County and Central Hospital, Sogn and Fjordane
County) since 2009. These two counties have a population of
620,527 (Statistics Norway 01.01.15). The glioma patients are
followed clinically and radiologically from their first seizure until
death. Neurological, oncological and paraclinical data are collected
every 6 months and at other admittances to the hospitals. By
10.12.2014, 20 patients had been registered with SE, once or on
several occasions. These 20 glioma patients had in total 31 SE. We
adhered to the old definition of SE as seizures lasting beyond
30 min, as this is regarded as the threshold for neurological
damage. We evaluated the medical records, prehospital informa-
tion, blood analyses, cerebral CT and MRI, EEG and follow-up data
of all patients. For descriptive purposes, all 31 status episodes were
included. In patients with multiple SE episodes, only the first
episode was included in the statistical analyses, to avoid the bias of
repeated measurements in one subject. The study was approved
by Regional Committees for Medical Research Ethics (REK 2008/
11243) and all patients gave a written consent.
3. Theory/calculation
3.1. Definitions
SE was defined as either 30 min of continuous seizure activity
or two or more sequential seizures without recovery of full
consciousness between the seizures [19]. Although the definition
was recently modified, we adhered to this version which is often
used in evaluating prognosis and has been used throughout the
study period [8,20]. Seizures were classified as focal SE without
consciousness impairment, focal SE with consciousness im-
pairment or secondary generalized SE. Refractory status epilepti-
cus (RSE) was defined as SE unresponsive to two AEDs and/or
requiring anesthetic agents for seizure control [21,22]. If the
patient was treated with two different benzodiazepines as first line
treatment, this was considered as the same AED.
The patients were grouped according to histological diagnosis
at onset of disease, or, in case of malignant transformation,
according to the most recent histological diagnosis. The LGG group
includes astrocytoma and oligodendroglioma of WHO grade II.
HGG includes anaplastic astrocytoma (WHO grade III) and
glioblastoma (GBM) (WHO grade IV) [23]. SE was categorized as
onset symptom if the seizure unfolded within 30 days prior to
glioma diagnosis. Progression was defined as radiographic changes
and clinical signs consistent with tumor progression within 30
days of the SE. Mortality was defined as death within 30 days after
the SE. Sequela was defined as a neurological deficit acquired
during the SE and documented in the medical record as persistent
at time of discharge, or at the next control appointment at the
hospital. Mild sequelae were defined as transient neurological
deficits lasting less than 1 month. Moderate sequelae were defined
as neurological deficits that were still present more than 1 month
after SE. Major sequelae were defined as permanent neurological
deficits which severely impaired functional ability.
3.2. Statistical methods
Statistical analyses were carried out in IBM SPSS Statistics for
Windows, versions 22.0 and 23.0 (Armonk, NY: IBM Corp).
Background variables were compared using cross-tables with
Fisher’s exact test of independence. Two-sided P values 0.05 were
interpreted as statistically significant dependence of variables.
4. Results
4.1. Patient and tumor characteristics
We identified 31 SE in 20 patients (Table 1). Five patients had
LGG and 15 had HGG. Two of the HGG were transformed from
previous LGG. The glioma was localized in the left hemisphere in
60%. Four tumors had a frontal location, ten were localized in the
parietal lobe or frontoparietal region, four were temporal lobe
tumors, one was occipital and one multilobal.
4.2. SE characteristics
The SE was secondary generalized in 15/31 (48%), focal with
consciousness impairment in eight (26%) and focal without
consciousness impairment in eight (26%) (Fig. 1). Repeated SE
was seen in seven of the 20 patients. Six of them had HGG,
including two patients with four SE each. The single LGG patient
had oligodendroglioma with SE as onset symptom and a second SE
several years later, at a time with no AED use.
The duration of SE varied from 30 min to 4 days (Table 2). The
focal seizures more often persisted longer than 5 h than the
secondary generalized seizures (P = 0.01). In patients where SE
led to initial glioma diagnosis (seven SE) or diagnosis of
progression (eight SE), we regarded the tumor as the main SE
trigger factor. In the other 16 SE, the tumor was stable and other
possible trigger factors were identified, as ongoing radiotherapy
with or without concomitant chemotherapy (four), intercurrent
disease (one) or changes in AED regimen (two). Most SE occurred
in a setting of well-controlled epilepsy with no or few seizures
the last month (Table 2). Four SE occurred in patients with no
prophylactic AED treatment, in addition to the seven SE which
heralded glioma diagnosis. Of the 20 SE in patients taking
prophylactic AEDs, only six were during polytherapy. Two
patients had serum AED levels below and one patient above
the reference areas at SE.
First line treatment was sufficient to terminate the seizures in
15/31 SE (48%) and second line treatment was needed in 7/31 (23%)
(Table 2). Eight cases were RSE; additional levetiracetam and/or
valproate were needed in six SE and general anesthesia with
Table 1
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propofol in two. Of the recurrent SE, four were treated successfully
with first line treatment, three needed second line treatment and
four were RSE. Considering only the first SE in every patient, 16/20
(80%) responded to first or second line treatment. None of the first
SE episodes required general anesthesia. SE in patients with tumor
progression was not proven to be statistically significant more
treatment refractory (P = 1.00).
4.3. Outcome after SE
Sequelae in terms of new neurological deficits were present
after 6/20 first SE (30%), one patient with tumor progression and
five patients without tumor progression. Mild sequelae were
aphasia and diminished hand motility. Moderate sequelae were
exacerbation of hemiparesis, aphasia and impaired balance. Major
sequelae were severe exacerbation of hemiparesis, dysarthria and
impaired consciousness. Patients with SE and tumor progression
had a worse outcome after SE (major sequelae or death within
3 months after SE) (P = 0.01).
At the end of this study, 16 patients were dead (Table 3). Mean
and median time from glioma diagnosis to death were
28.5 months and 20 months (minimum 3, maximum 152).
Follow-up from glioma diagnosis to end of study for the four
survivors were 12–52 months. No patient died during SE or earlier
than 3 weeks after SE. Six patients died within 3 months after SE, of
which two were de novo GBM with recurrent SE. One of these
patients died 2 months after her second SE and the other patient
died 21 days after his fourth SE. Death within 3 months occurred in
0% of LGG and 40% of HGG. Additionally, two of the six patients
died within 30 days of SE; one had transformed GBM and one
anaplastic astrocytoma, which gave a 30 days’ mortality rate of
0% for LGG and 20% for HGG.
5. Discussion
The majority of SE occurred in HGG patients. This is surprising
as the survival time is shorter in HGG and seizures are more
frequent in LGG than in HGG. Advances in oncological therapy may
affect the prevalence of seizures in glioma. Temozolomide has
prolonged the survival time for GBM patients and may thus
Fig. 1. Classification of SE semiology (n = 31).
Table 2











>30 min–1 h 6
>1–5 h 13
>5–24 h 4
>24 h–5 days 6
Previous seizures







Diazepam and/or midazolam 15










Death within 3 months 1






Death within 3 months 5
a Refractory SE was defined as the need of more
medication than first and second line treatment.
b Sequela was defined as a neurological deficit
acquired at time of SE and persistent at hospital
discharge or at the next control appointment.
Table 3
Outcome stratified by histological features.




Median (months) Median (months)
Time until death (n = 16)
Oligodendroglioma 1 152 152
Astrocytoma 1 27 27
Anaplastic astrocytoma 2 8.5 7.5
Glioblastoma 12 20 6
Follow-up of survivors (n = 4)
Oligodendroglioma 2 51 46
Astrocytoma 1 12 12
Anaplastic astrocytoma 1 13 13
Glioblastoma 0
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increase the incidence of epilepsy in this group. The pathophysiol-
ogy of epilepsy in LGG and HGG is different, as the slow growth in
LGG allows for development of functional changes whereas the
rapid growth in HGG leads to distortion of cortical tissue and
edema [24,25]. Even though single or recurrent seizures are more
common in LGG, the risk of tumor associated SE appears to be
directly proportional to tumor grade [26]. HGG is fivefold as
common as LGG in Europe [27] but as epilepsy was the major
inclusion criterion, LGG constitutes as many as half of the patients
in our database. Nevertheless, we found that 75% of first SE was in
HGG, compared to 44% in a previous study [16]. Rosati et al. found a
lower frequency of epilepsy in de novo GBM than in secondary
GBM, supporting the hypothesis that the mechanisms of seizure in
slow-growing and fast-growing tumors are different [24]. Aggres-
sive tumors with insufficient blood supply cause intratumoral
hypoxia and acidosis that may extend to surrounding tissue and
cause glial swelling and damage leading to risk of seizures [28].
Two of our patients had secondary GBM. Other factors may also
explain the higher frequency of SE in HGG. Chemotherapy may
affect AED levels [29], and although seizure control usually
improves by radiotherapy, some patients have seizures due to
acute radiation encephalopathy. The four patients with SE related
to oncological treatment were all GBM. Corticosteroids decrease
susceptibility to seizures in laboratory studies [30], and are used
liberally as anti-edema therapy in HGG. Dose tapering may
increase susceptibility to seizures, also due to increased edema,
although no studies investigate this issue. Most HGG in our study
were treated with dexamethasone.
In half of the SE, the semiology was secondary generalized
seizures. Most previous studies of SE in glioma have not defined
seizure type [18] or only included particular seizure types [15,17],
thus making a general comparison of semiology with these studies
challenging. Brain tumors have earlier been regarded as having the
propensity to cause focal SE rather than secondary generalized SE
[31]. However, the majority of brain tumor patients with SE in an
Italian study [16] also suffered secondary generalized SE, similar to
our results. For SE in general, secondary generalized seizures are
reported to be observed in 19–66% of patients [32]. The recurrence
rate was 35%, which is roughly comparable with a recent estimate
not limited to tumor patients of 32% [33].
The glioma was most often located in the parietal lobe. Parietal
tumors are easier to operate, with improved survival and thereby
longer possibility for developing SE. Another reason for our finding
can be that the risk of epileptic seizures is substantial in tumors of
the parietal lobes [34,35].
Four times as many males than females were affected by SE,
which cannot be explained by the modest gender difference in
glioma. SE in general is more common among men, which has been
explained by the higher male frequency of cerebrovascular disease
[36]. However, our findings in a tumor population suggest that
gender differences in epileptogenicity or other factors might be
important.
More than 70% of the SE in this study was controlled by first or
second line treatment, of which 75% had a well-controlled seizure
situation prior to SE. About one fourth were treatment refractory,
which is toward the lower margin of estimations reported for SE
with other etiology than tumor [12]. Refractory SE has been
estimated to 23–43% in different studies and is associated with high
morbidity and mortality [37–40]. SE associated with tumor
progression was not less treatment responsive but had worse
outcome, which could be due to SE, the tumor progression or both.
Thus, evaluating outcome measures with respect to SE are
uncertain in this subgroup. However, we hypothesize that SE in
the context of tumor progression might exacerbate the neurological
decline. We found a similar 30 days’ mortality rate for HGG with SE
as a previous study, 20% vs 18% [16]. Tumor progression was known
in all cases that led to death within 3 months of SE except one. As SE
is a medical emergency and progression may be unknown at the
time of hospital admittance, we propose that all SE in glioma are
treated aggressively until tumor status is clarified. In a setting of
acknowledged tumor progression and RSE, the clinician may decide
to withhold therapy requiring ICU – however, our data show that
third line treatment is unnecessary in most cases. In addition, for
palliative and psychological reasons, it is highly important to avoid
SE in the terminal phase, and we suggest that effective SE therapy
should not be withheld in any patient with clinical SE and glioma.
There were no losses to follow-up. Non-convulsive SE might be
underdiagnosed in patients with marked consciousness im-
pairment within the last weeks of life and dying at home or in
nursing homes. The two neurological departments participating in
the study covers the complete population in a defined geographical
cohort. This material therefore has minimal selection bias,
reflecting the total population of patients with a glioma and SE,
recorded prospectively during 7 years.
6. Conclusion
Our results show that SE should be treated as aggressively in
glioma patients as in patients with no tumor. The response to
treatment was good and general anesthesia seldom required. SE
arose in patients with clinically and radiologically stable disease as
often as in patients with untreated tumor or tumor in progression.
Patients with SE triggered by tumor progression were not more
refractory to treatment than patients with a stable glioma.
Ethical publication statement
We confirm that we have read the journal’s position on issues
involved in ethical publication and affirm that this report is
consistent with those guidelines.
Conflict of interest statement
The authors received no funding for this study. None of the
authors has any conflict of interest to disclose.
References
[1] Ruda R, Soffietti R. What is new in the management of epilepsy in gliomas?
Curr Treat Options Neurol 2015;17:351.
[2] Vecht CJ, Wilms EB. Seizures in low- and high-grade gliomas: current man-
agement and future outlook. Expert Rev Anticancer Ther 2010;10:663–9.
[3] Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: new
insights and evidence-based management. Oncologist 2014;19:751–9.
[4] Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during
follow-up of patients treated for primary brain tumors. Neurology 2005;65:
212–5.
[5] Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas.
Epilepsia 2013;54(Suppl. 9):12–7.
[6] Chen JW, Naylor DE, Wasterlain CG. Advances in the pathophysiology of status
epilepticus. Acta Neurol Scand 2007;115:7–15.
[7] Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS
guideline on the management of status epilepticus in adults. Eur J Neurol
2010;17:348–55.
[8] Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A
definition and classification of status epilepticus – report of the ILAE Task Force
on Classification of Status Epilepticus. Epilepsia 2015;56:1515–23.
[9] Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of
status epilepticus. Epilepsia 1999;40:120–2.
[10] Scott RC, Surtees RA, Neville BG. Status epilepticus: pathophysiology, epide-
miology, and outcomes. Arch Dis Child 1998;79:73–7.
[11] DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A
prospective, population-based epidemiologic study of status epilepticus in
Richmond, Virginia. Neurology 1996;46:1029–35.
[12] Claassen J, Lokin JK, Fitzsimmons BF, Mendelsohn FA, Mayer SA. Predictors of
functional disability and mortality after status epilepticus. Neurology
2002;58:139–42.
[13] Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status
epilepticus. Epilepsia 1994;35:27–34.
K.M. Knudsen-Baas et al. / Seizure 40 (2016) 76–80 79
[14] Sagduyu A, Tarlaci S, Sirin H. Generalized tonic-clonic status epilepticus:
causes, treatment, complications and predictors of case fatality. J Neurol
1998;245:640–6.
[15] Marcuse LV, Lancman G, Demopoulos A, Fields M. Nonconvulsive status
epilepticus in patients with brain tumors. Seizure 2014;23:542–7.
[16] Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in
patients with neoplasms. Arch Neurol 2006;63:1746–9.
[17] Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The
course of seizure disorders in patients with malignant gliomas. Arch Neurol
1995;52:717–24.
[18] Janz D. Status epilepticus and frontal lobe lesions. J Neurol Sci 1964;1:446–57.
[19] Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for
status epilepticus. Cochrane Database Syst Rev 2014;9:CD003723.
[20] Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiol-
ogy and Prognosis, International League Against Epilepsy. Epilepsia 1993;34:
592–6.
[21] Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. Predictors of
outcome in refractory status epilepticus. JAMA Neurol 2013;70:72–7.
[22] Kwan P, Brodie MJ. Definition of refractory epilepsy: defining the indefinable?
Lancet Neurol 2010;9:27–9.
[23] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The
2007 WHO classification of tumours of the central nervous system. Acta
Neuropathol 2007;114:97–109.
[24] Rosati A, Tomassini A, Pollo B, Ambrosi C, Schwarz A, Padovani A, et al. Epilepsy
in cerebral glioma: timing of appearance and histological correlations. J
Neurooncol 2009;93:395–400.
[25] de Groot M, Reijneveld JC, Aronica E, Heimans JJ. Epilepsy in patients with a
brain tumour: focal epilepsy requires focused treatment. Brain 2012;135:
1002–16.
[26] Goonawardena J, Marshman LA, Drummond KJ. Brain tumour-associated
status epilepticus. J Clin Neurosci 2015;22:29–34.
[27] Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology
of glial and non-glial brain tumours in Europe. Eur J Cancer 2012;48:1532–42.
[28] You G, Sha Z, Jiang T. The pathogenesis of tumor-related epilepsy and its
implications for clinical treatment. Seizure 2012;21:153–9.
[29] Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme
induction with antiepileptic drugs: cause for concern? Epilepsia 2013;54:
11–27.
[30] Velisek L. Prenatal corticosteroid exposure alters early developmental seizures
and behavior. Epilepsy Res 2011;95:9–19.
[31] Neligan A, Shorvon SD. Frequency and prognosis of convulsive status
epilepticus of different causes: a systematic review. Arch Neurol
2010;67:931–40.
[32] Dupont S, Crespel A. [Status epilepticus: epidemiology, definitions and clas-
sifications]. Rev Neurol (Paris) 2009;165:307–14.
[33] Tsetsou S, Novy J, Rossetti AO. Recurrence of status epilepticus: prognostic role
and outcome predictors. Epilepsia 2015;56:473–8.
[34] Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in the cancer patient. Cancer
Chemother Pharmacol 2011;67:489–501.
[35] Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, et al.
Frequency of seizures in patients with newly diagnosed brain tumors: a
retrospective review. Clin Neurol Neurosurg 2007;109:634–8.
[36] Knake S, Rosenow F, Vescosi M, Oertel WH, Mueller HH, Wirbatz A, et al.
Incidence of status epilepticus in adults in Germany: a prospective, popula-
tion-based study. Epilepsia 2001;42:714–8.
[37] Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective
observational study. Epilepsia 2010;51:251–6.
[38] Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF.
Refractory status epilepticus: frequency, risk factors, and impact on outcome.
Arch Neurol 2002;59:205–10.
[39] Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of
refractory status epilepticus treated in a neurological intensive care unit.
J Neurol Neurosurg Psychiatry 2005;76:534–9.
[40] Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus:
effect of treatment aggressiveness on prognosis. Arch Neurol 2005;62:
1698–702.





 Supplementary material, paper II 
 




Online Resource 1 Examination of potential risk factors a for anxiety in patients with glioma grade II-III 
and grade IV the first two years after glioma diagnosis 
 
Glioma II-III               N=28                   %                  HR         95% CI P-value 
Levetiracetam                     11                 39 2.39 1.04 5.50 0.04 
Carbamazepine 5 18 1.48 0.62 3.53 0.38 
Oxcarbazepine 2 7 0.31 0.04 2.34 0.25 
Valproate 5 18 1.55 0.65 3.66 0.32 
Lamotrigine 2 7 1.30 0.47 3.60 0.61 
Grade III glioma 17 61 1.68 0.83 3.39 0.15 
Epilepsy 19 68 1.21 0.53 2.75 0.65 
No surgery 0 0 0.31 0.03 3.05 0.32 
Biopsy 5 18 0.95 0.46 1.99 0.90 
No radiotherapy 3 11 1.48 0.58 3.81 0.41 
Temozolomide 23 82 6.54 2.61 16.35 <0.01 
Systemic steroids 20 71 2.92 1.49 5.73 <0.01 
Pain 22 79 1.55 0.81 2.97 0.19 
Frontal tumor 6 21 0.68 0.33 1.38 0.28 
Female 16 57 1.50 0.81 2.77 0.20 
Age <20  2 7 2.14 0.65 7.03 0.21 
Age 20-39  9 32 0.86 0.41 1.80 0.69 
Age 40-59  9 32 Reference    
Age 60-79   6 21 1.10 0.48 2.52 0.82 
Age 80+  2 7 27.93 4.73 164.76 <0.01 
Glioma IV                    N=144              %                 HR    95% CI P-value 
Levetiracetam 37                 26 1.47 0.85 2.54 0.17 
Carbamazepine 8 6 1.16 0.60 2.21 0.66 
Oxcarbazepine 12 8 1.14 0.57 2.29 0.71 
Valproate 25 17 0.66 0.36 1.19 0.17 
Lamotrigine 8 6 1.63 0.78 3.39 0.19 
Epilepsy 75 52 0.95 0.61 1.47 0.82 
No surgery 6 4 0.77 0.30 1.93 0.57 
Biopsy 20 14 1.49 0.97 2.28 0.07 
No radiotherapy 9 6 1.29 0.65 2.59 0.47 
Temozolomide 116 81 1.88 1.23 2.87 <0.01 
Systemic steroids 99 69 1.55 1.14 2.10 <0.01 
Pain 113 78 2.13 1.55 2.92 <0.01 
Frontal tumor 35 24 0.93 0.66 1.31 0.66 
Female 76 53 1.50 1.13 2.00 <0.01 
Age <20  1 1 0.65 0.16 2.67 0.55 
Age 20-39  4 3 0.50 0.23 1.09 0.08 
Age 40-59  63 44 1.07 0.78 1.46 0.68 
Age 60-79   67 47 Reference    
Age 80+  9 6 1.33 0.61 2.87 0.47 
aHR=Hazard ratios. CI=Confidence intervals. Age in years 
 
 
Online Resource 2 Examination of potential risk factors a for depression in patients with  
glioma grade II-III and grade IV the first two years after glioma diagnosis 
 
Glioma II-III               N=39                   %                 HR   95% CI P-value 
Levetiracetam              13 33 1.33 0.37 4.72 0.66 
Carbamazepine 5 13 0.83 0.23 2.92 0.77 
Oxcarbazepine 3 8 1.63 0.46 5.85 0.45 
Valproate 11 28 1.84 0.69 4.85 0.22 
Lamotrigine 6 15 0.55 0.12 2.48 0.43 
Grade III glioma 10 26 0.84 0.38 1.85 0.66 
Epilepsy 25 64 0.55 0.25 1.22 0.14 
No surgery 3 8 1.37 0.43 4.37 0.59 
Biopsy 4 10 0.72 0.29 1.77 0.47 
No radiotherapy 12 31 0.84 0.37 1.88 0.67 
Temozolomide 20 51 0.77 0.35 1.69 0.51 
Systemic steroids 22 56 0.98 0.50 1.94 0.96 
Pain 34 87 3.65 1.88 7.08 <0.01 
Frontal tumor 13 33 0.88 0.47 1.64 0.69 
Female 18 46 1.29 0.72 2.32 0.39 
Age <20  0 0 0.00 0.00 0.00 0.00 
Age 20-39  10 26 0.80 0.41 1.53 0.49 
Age 40-59  19 49 Reference    
Age 60-79   9 23 0.95 0.43 2.11 0.90 
Age 80+  1 3 1.62 0.20 13.37 0.65 
Glioma IV                     N=109                  %                 HR             95% CI    P-value 
Levetiracetam 17 16 0.93 0.34 2.55 0.88 
Carbamazepine 9 8 0.71 0.21 2.40 0.58 
Oxcarbazepine 9 8 1.32 0.44 3.98 0.63 
Valproate 12 11 0.48 0.16 1.46 0.20 
Lamotrigine 4 4 0.83 0.19 3.62 0.81 
Epilepsy 43 39 0.54 0.28 1.04 0.07 
No surgery 6 6 0.95 0.37 2.41 0.91 
Biopsy 17 16 1.72 1.04 2.85 0.04 
No radiotherapy 6 6 0.87 0.38 2.03 0.75 
Temozolomide 77 71 0.90 0.57 1.43 0.67 
Systemic steroids 72 66 1.19 0.82 1.73 0.36 
Pain 70 64 1.50 1.03 2.20 0.04 
Frontal tumor 16 15 0.55 0.33 0.91 0.02 
Female 57 52 1.38 0.96 1.98 0.08 
Age <20  1 1 0.54 0.07 3.93 0.54 
Age 20-39  5 5 1.10 0.46 2.60 0.83 
Age 40-59  41 38 1.23 0.82 1.84 0.32 
Age 60-79   53 49 Reference    
Age 80+  9 8 1.26 0.59 2.73 0.55 
aHR=Hazard ratios. CI=Confidence intervals. Age in years 
 
Online Resource 3 Medication during the year prior to the glioma diagnosis (N observed), compared to 
the total Norwegian population (N expected) a 
 
 
aSIR=Standardized incidence ratios. CI=Confidence intervals  
Medication Glioma grade Strata N observed  N expected   SIR 95% CI 
Anxiolytics 
 
All 311 139 2.24 2.00 2.50 
 
II-III Epilepsy 15 1 12.76 7.69 21.17 
  
No epilepsy 67 29 2.30 1.81 2.93 
 
IV Epilepsy 8 2 5.02 2.51 10.04 
  
No epilepsy 221 107 2.06 1.81 2.36 
Hypnotics  All 370 185 2.00 1.81 2.21 
and sedatives II-III Epilepsy 9 2 5.30 2.76 10.18 
  
No epilepsy 75 35 2.15 1.72 2.70 
 
IV Epilepsy 2 2 0.81 0.20 3.24 
  
No epilepsy 284 146 1.94 1.73 2.18 
 
 
All 172 128 1.35 1.16 1.56 
Antidepressants II-III Epilepsy 1 2 0.55 0.08 3.92 
  
No epilepsy 32 31 1.05 0.74 1.48 
 
IV Epilepsy 5 1 3.72 1.55 8.94 
    No epilepsy 134 94 1.42 1.20 1.69 

Online Resource 4 Examination of potential risk factors a for anxiety in patients with glioma grade II-III 
and grade IV without depression 
 
Glioma II-III               N=59                   %                  HR         95% CI P-value 
Levetiracetam 32 54 4.30 2.27 8.14 <0.01 
Carbamazepine 15 25 1.49 0.77 2.89 0.24 
Oxcarbazepine 8 14  0.99 0.36 2.67 0.98 
Valproate 19 32 2.28 1.19 4.38 0.01 
Lamotrigine 13 22 1.60 0.77 3.34 0.21 
Grade III glioma 25 42 1.94 1.00 3.78 0.05 
Epilepsy 49 83 0.83 0.38 1.81 0.64 
No surgery 0 
 
    
Biopsy 16 27 1.29 0.70 2.40 0.41 
No radiotherapy 16 27 1.38 0.63 3.01 0.42 
Temozolomide 50 85 5.59 2.60 12.04 <0.01 
Systemic steroids 46 78 4.29 2.29 8.01 <0.01 
Pain 47 80 1.14 0.63 2.06 0.67 
Frontal tumor 21 36 1.13 0.63 2.01 0.68 
Female 29 49 1.44 0.83 2.49 0.19 
Age <20  7 12 2.66 1.04 6.82 0.04 
Age 20-39  16 27 0.71 0.37 1.36 0.30 
Age 40-59  26 44 Reference    
Age 60-79   9 15 0.77 0.35 1.71 0.53 
Age 80+  1 2 27.60 2.93 260.12 <0.01 
Glioma IV                    N=163              %                 HR    95% CI P-value 
Levetiracetam 40 25 1.58 0.91 2.74 0.10 
Carbamazepine 14 9 1.21 0.63 2.32 0.58 
Oxcarbazepine 10 6 0.98 0.46 2.11 0.96 
Valproate 30 18 0.60 0.33 1.11 0.11 
Lamotrigine 15 9 1.83 0.90 3.73 0.10 
Epilepsy 89 55 1.07 0.68 1.70 0.76 
No surgery 5 3 0.65 0.24 1.79 0.40 
Biopsy 18 11 1.17 0.70 1.93 0.55 
No radiotherapy 9 6 1.44 0.69 3.01 0.34 
Temozolomide 137 84 1.84 1.15 2.95 <0.01 
Systemic steroids 118 72 1.73 1.24 2.42 <0.01 
Pain 130 80 2.12 1.50 2.99 <0.01 
Frontal tumor 44 27 1.17 0.83 1.67 0.37 
Female 77 47 1.38 1.01 1.89 0.04 
Age <20  2 1 0.76 0.18 3.13 0.70 
Age 20-39  8 5 0.49 0.23 1.03 0.06 
Age 40-59  69 42 0.90 0.64 1.27 0.57 
Age 60-79   76 47 Reference    
Age 80+  8 5 1.47 0.65 3.34 0.36 
aHR=Hazard ratios. CI=Confidence intervals. Age in years 
 
 
Online Resource 5 Examination of potential risk factors a for depression in patients with  
glioma grade II-III and grade IV without anxiety 
 
Glioma II-III               N=38                   %                 HR   95% CI P-value 
Levetiracetam 14 37 2.57 0.86 7.69 0.09 
Carbamazepine 7 18 1.35 0.43 4.28 0.61 
Oxcarbazepine 2 5 0.61 0.07 5.04 0.65 
Valproate 10 26 4.52 1.59 12.82 <0.01 
Lamotrigine 9 24 3.67 1.20 11.19 0.02 
Grade III glioma 8 21 0.85 0.34 2.11 0.73 
Epilepsy 21 55 0.20 0.07 0.57 <0.01 
No surgery 3 8 1.74 0.45 6.66 0.42 
Biopsy 4 11 0.72 0.24 2.16 0.56 
No radiotherapy 12 32 0.68 0.25 1.86 0.45 
Temozolomide 18 47 0.38 0.15 0.94 0.04 
Systemic steroids 23 61 2.27 1.06 4.86 0.03 
Pain 30 79 3.70 1.67 8.22 <0.01 
Frontal tumor 17 45 1.39 0.70 2.76 0.35 
Female 14 37 0.75 0.38 1.49 0.41 
Age <20  0 0     
Age 20-39  15 39 1.07 0.50 2.32 0.85 
Age 40-59  14 37 Reference    
Age 60-79   9 24 1.39 0.59 3.28 0.45 
Age 80+  0 0     
Glioma IV                     N=86                  %                 HR             95% CI    P-value 
Levetiracetam 9 10 0.98 0.28 3.47 0.97 
Carbamazepine 10 12 2.24 0.81 6.17 0.12 
Oxcarbazepine 5 6 0.62 0.08 4.85 0.65 
Valproate 13 15 1.59 0.57 4.44 0.37 
Lamotrigine 5 6 2.62 0.73 9.39 0.14 
Epilepsy 33 38 0.31 0.13 0.71 0.01 
No surgery 5 6 0.95 0.34 2.68 0.92 
Biopsy 13 15 1.59 0.86 2.93 0.14 
No radiotherapy 5 6 0.81 0.30 2.20 0.68 
Temozolomide 58 67 0.85 0.49 1.45 0.55 
Systemic steroids 60 70 1.33 0.85 2.07 0.21 
Pain 50 58 1.14 0.73 1.79 0.56 
Frontal tumor 13 15 0.59 0.32 1.07 0.08 
Female 39 45 1.20 0.78 1.85 0.40 
Age <20  1 1 0.70 0.09 5.12 0.72 
Age 20-39  3 3 0.63 0.19 2.08 0.45 
Age 40-59  31 36 1.02 0.63 1.65 0.94 
Age 60-79   43 50 Reference    
Age 80+  8 9 1.50 0.65 3.46 0.34 
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